CCDC85B: A Promising Drug Target and Biomarker for the Treatment of Neoplasia

Target Name: CCDC85B

NCBI ID: G11007

CCDC85B

CCDC85B: A Promising Drug Target and Biomarker for the Treatment of Neoplasia

Neoplasia, the formation of new cancerous tissue in existing organs or tissues, is a leading cause of morbidity and mortality worldwide. The development of new treatments for cancer is crucial for improving survival rates and quality of life. CCDC85B, a protein that belongs to the Cdc85 family and is expressed in various tissues and organs, has been identified as a potential drug target and biomarker for the treatment of neoplasia.

CDC85B: Structure and Function

The Cdc85 gene is located on chromosome 6p21.3 and encodes a protein that consists of a unique coiled-coil domain, a transmembrane region, and an N-terminus. The coiled-coil domain is the protein's most distinctive feature, as it plays a crucial role in its structural stability and stability.

The Cdc85 protein functions as a negative regulator of the RAS/MAPK signaling pathway, which is involved in cell growth, survival, and angiogenesis. The RAS/MAPK pathway is a well-established target for cancer therapy, as it promotes the formation of cancer stem cells and promotes the growth and progression of cancer. By inhibiting the RAS/MAPK pathway, Cdc85B has been shown to have anti-tumor effects.

Cdc85B has been shown to interact with various proteins, including G protein-coupled receptors (GPCRs), which are involved in cellular signaling pathways. The interaction between Cdc85B and GPCRs has led to the hypothesis that Cdc85B may be a drug target for the treatment of neoplasia.

CDC85B as a Biomarker

One of the challenges in the development of cancer treatments is the lack of specific biomarkers that can predict disease outcomes. Cdc85B has been shown to be expressed in various types of cancer, including breast, lung, and ovarian cancer. Additionally, Cdc85B has been shown to be overexpressed in neoplasia, which suggests that it may be a useful biomarker for the diagnosis and evaluation of neoplasia.

In addition to its potential as a biomarker, Cdc85B has also been identified as a potential drug target. The inhibition of the RAS/MAPK pathway by Cdc85B has been shown to have anti-tumor effects, which suggests that it may be a useful target for the treatment of neoplasia.

CDC85B as a Potential Drug Target

The inhibition of the RAS/MAPK pathway by Cdc85B has led to the hypothesis that it may be a potential drug target for the treatment of neoplasia. Neoplasia is a condition in which new cancerous tissue forms in existing organs or tissues. The formation of new cancerous tissue is fueled by the RAS/MAPK pathway, which promotes the growth and survival of cancer cells. By inhibiting this pathway, Cdc85B has been shown to have anti-tumor effects.

Cdc85B has been shown to interact with various proteins, including G protein-coupled receptors (GPCRs), which are involved in cellular signaling pathways. The interaction between Cdc85B and GPCRs has led to the hypothesis that Cdc85B may be a drug target for the treatment of neoplasia.

CDC85B has also been shown to play a role in the regulation of cell adhesion. The coiled-coil domain of Cdc85B is involved in the regulation of cell-cell adhesion, which is critical for the maintenance of tissue structure and the development of cancer.

Conclusion

In conclusion, CCDC85B is a protein that has been identified as a potential drug target for the treatment of neoplasia due to its interaction with the RAS/MAPK pathway and its role in the regulation of cell adhesion. Further research is needed to

Protein Name: Coiled-coil Domain Containing 85B

Functions: Functions as a transcriptional repressor (PubMed:17014843). May inhibit the activity of CTNNB1 in a TP53-dependent manner and thus regulate cell growth (PubMed:17873903). May function in adipocyte differentiation, negatively regulating mitotic clonal expansion (By similarity). Plays a role in cell-cell adhesion and epithelium development through its interaction with proteins of the beta-catenin family (By similarity)

The "CCDC85B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC85B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets